Detailed clinical research summaries.
STEP trials
STEP-1 (14.9% at 68 wk), STEP-4, STEP-HFpEF.
SURMOUNT trials
SURMOUNT-1 (20.9% at 72 wk), SURMOUNT-OSA.
SELECT — CV
20% MACE reduction (NEJM 2023).
FLOW — kidney
24% reduction major kidney events (NEJM 2024).
SUSTAIN — sema T2D
Foundational T2D program.
SURPASS — tirz T2D
SURPASS-3 head-to-head with insulin.
SYNERGY-NASH
44–62% MASH resolution at 52 wk.
ESSENCE — sema MASH
~62% MASH resolution at 72 wk (interim May 2026).
Contraindications
MTC, MEN-2, pregnancy.
Drug interactions
Insulin, anesthesia, OCP, pregnancy.
Mechanism of action
Receptor biology, multi-organ effects.